Skinvisible, Inc. (SKVI)
OTCMKTS · Delayed Price · Currency is USD
0.4926
0.00 (0.00%)
Jan 21, 2026, 9:30 AM EST
Skinvisible Employees
Skinvisible had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$10,000
Profits / Employee
-$245,453
Market Cap
2.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2021 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2020 | 2 | -1 | -33.33% | 2 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longevity Health Holdings | 15 |
| DSwiss | 13 |
| PURE Bioscience | 12 |
| Peregrine Industries | 4 |
| Sentient Brands Holdings | 1 |
Skinvisible News
- 4 months ago - Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection - Accesswire
- 1 year ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 1 year ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 1 year ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 1 year ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 1 year ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 2 years ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire